HALO Stock News 7.37 05/09/2014 18:58:00 Halozyme Therapeutics
Post# of 273323
Posted On: 05/09/2014 7:58:04 PM
Halozyme Therapeutics (HALO) 7.37 $HALO
Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2014 Health Care Conference
PR Newswire - Wed May 07, 3:30PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas, NV, on Wednesday, May 14, 2014 at 1:40 p.m. PT/4:40 p.m. ET. Dr. Helen Torley, President and Chief Executive Officer, will provide a corporate overview.
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2d32kc/type_1_diabetes) has announced the addition of the "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - Johnson & Johnson - Boehringer Ingelheim GmbH - Osiris Therapeutics, Inc. - Sanofi - AstraZeneca PLC - Eli Lilly and Company - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - AbGenomics International, Inc. - Novo Nordisk A/S - Generex Biotechnology Corporation - BioLineRx, Ltd. - Kissei Pharmaceutical Co., Ltd. - Pfizer Inc. - Cell Therapeutics, Inc. - Hadasit Medical Research Services & Development Ltd - Biodel Inc. - MannKind Corporation - Halozyme Therapeutics, Inc. - Merck KGaA - Evotec AG - Karo Bio AB - Ligand Pharmaceuticals, Inc. - Opexa Therapeutics, Inc. - Compugen Ltd. - Oramed Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/2d...1_diabetes
Downtrend Call Working As Halozyme Therapeutics Stock Falls 47.0% (HALO)
Comtex SmarTrend(R) - Tue May 06, 9:36AM CDT
SmarTrend identified a Downtrend for Halozyme Therapeutics (NASDAQ:HALO) on March 13th, 2014 at $13.63. In approximately 2 months, Halozyme Therapeutics has returned 47.03% as of today's recent price of $7.22.
Halozyme to Host first Quarter 2014 Financial Results Conference Call
PR Newswire - Mon May 05, 4:00PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2014 on Monday, May 12, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the first quarter 2014.
46.5% Return Seen to Date on SmarTrend Halozyme Therapeutics Call (HALO)
Comtex SmarTrend(R) - Tue Apr 29, 9:08AM CDT
SmarTrend identified a Downtrend for Halozyme Therapeutics (NASDAQ:HALO) on March 13th, 2014 at $13.63. In approximately 2 months, Halozyme Therapeutics has returned 46.52% as of today's recent price of $7.29.
Global Metastatic Pancreatic Cancer Therapeutics Pipeline Review 2014 - Analysis of 27 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gctlqw/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Pancreatic Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Adherex Technologies Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - FibroGen, Inc. - Novartis AG - Pfizer Inc. - Celgene Corporation - Bayer AG - Halozyme Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - Immunomedics, Inc. - Synta Pharmaceuticals Corp. - NanoCarrier Co., Ltd. - Rexahn Pharmaceuticals, Inc. - Insys Therapeutics, Inc. - OncoMed Pharmaceuticals, Inc. - Merrimack Pharmaceuticals, Inc. - Pharma Mar, S.A. - AB Science - Oncovir, Inc. - ParinGenix, Inc. - Regulon Inc. - Fountain Biopharma Inc. - Oncozyme Pharma Inc. - AbbVie Inc. Drug Profiles - paclitaxel albumin-bound - irinotecan sucrosofate liposomal - masitinib - cisplatin liposomal - cisplatin - refametinib - selumetinib sulfate - trametinib dimethyl sulfoxide - docetaxel - paclitaxel albumin-bound - ganetespib - RX-0201 - irinotecan sucrosofate liposomal - PGX-100 - lurbinectedin - yttrium Y 90 clivatuzumab tetraxetan - Cancer Inhibitor Macrobeads - TL-118 - LY-2090314 - hydroxychloroquine - LY-2495655 - PEGPH-20 - M-402 - pentamidine isethionate - veliparib - galunisertib - ADH-1 - FG-3019 - demcizumab - LCL-161 For more information visit http://www.researchandmarkets.com/research/gctlqw/metastatic
Halozyme Therapeutics Has Returned 43.6% Since SmarTrend Recommendation (HALO)
Comtex SmarTrend(R) - Mon Apr 21, 4:39PM CDT
SmarTrend identified a Downtrend for Halozyme Therapeutics (NASDAQ:HALO) on March 13th, 2014 at $13.63. In approximately 1 month, Halozyme Therapeutics has returned 43.58% as of today's recent price of $7.69.
Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Halozyme Therapeutics, Inc.
Business Wire - Mon Apr 21, 1:02PM CDT
Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of Halozyme Therapeutics, Inc. (NASDAQ: HALO) violated state or federal laws. Halozyme is a biopharmaceutical company that researches, develops and commercializes human enzymes.
1 of These 3 Cratering Biotechs is a Buy
George Budwell, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
At the start of the year, the theme seemed to be that biotech was in for another banner year, propelled by a suite of newly launch drugs that would go on to become blockbusters. These rosy prognostications were made despite broad-based biotech funds...
Robbins Arroyo LLP Is Investigating the Officers and Directors of Halozyme Therapeutics, Inc. on Behalf of Shareholders
PR Newswire - Thu Apr 17, 3:20PM CDT
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Halozyme Therapeutics, Inc. (NASDAQ: HALO) breached their fiduciary duties to shareholders. Halozyme is a biopharmaceutical company that researches, develops, and commercializes human enzymes that facilitate the delivery of injected drugs and fluids.
Coca-Cola and MasterCard are big market movers
AP - Tue Apr 15, 4:01PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
5 of Last Week's Biggest Losers
Rick Munarriz, The Motley Fool - Motley Fool - Sun Apr 13, 6:00AM CDT
There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers. Company April 11 Weekly Loss voxeljet AG $15.10 40% World...
Nasdaq stocks posting largest percentage increases
AP - Fri Apr 11, 12:52PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Halozyme Study Under Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:40PM CDT
Halozyme announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on patient enrollment and dosing of PEGPH20 in an ongoing phase II study.
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 09, 11:46AM CDT
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.
Halozyme Announces Clinical Hold of PEGPH20 Pancreatic Cancer Trial Following Voluntary Halt of Trial by Halozyme
PR Newswire - Wed Apr 09, 7:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the United States Food and Drug Administration (FDA) informed the company yesterday that a clinical hold has been placed on patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer. According to the FDA, this action was being taken in view of the company's recent decision to temporarily halt enrollment and dosing of PEGPH20 in the Phase 2 trial.
Healthcare Companies Report Regulatory Affirmations, MPA Inspections, Enrollment in Trials, Stock Movements - Analyst Notes on Halozyme, Align Technology, Cambrex, Receptos, and Anacor Pharmaceuticals
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Halozyme Therapeutics, Inc. (NASDAQ: HALO), Align Technology Inc. (NASDAQ: ALGN), Cambrex Corporation. (NYSE: CBM), Receptos, Inc. (NASDAQ: RCPT), and Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
3 Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 08, 12:45PM CDT
Just as we examine companies each week that may be rising past their fair values , we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with stocks wallowing at 52-week lows, I think...
Halozyme Falls on Phase II Study Halt - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 11:10AM CDT
Halozyme's shares fell after the company announced its decision to temporarily halt patient enrollment and dosing of PEGPH20 in phase II study.
Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2014 Health Care Conference
PR Newswire - Wed May 07, 3:30PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas, NV, on Wednesday, May 14, 2014 at 1:40 p.m. PT/4:40 p.m. ET. Dr. Helen Torley, President and Chief Executive Officer, will provide a corporate overview.
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2d32kc/type_1_diabetes) has announced the addition of the "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - Johnson & Johnson - Boehringer Ingelheim GmbH - Osiris Therapeutics, Inc. - Sanofi - AstraZeneca PLC - Eli Lilly and Company - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - AbGenomics International, Inc. - Novo Nordisk A/S - Generex Biotechnology Corporation - BioLineRx, Ltd. - Kissei Pharmaceutical Co., Ltd. - Pfizer Inc. - Cell Therapeutics, Inc. - Hadasit Medical Research Services & Development Ltd - Biodel Inc. - MannKind Corporation - Halozyme Therapeutics, Inc. - Merck KGaA - Evotec AG - Karo Bio AB - Ligand Pharmaceuticals, Inc. - Opexa Therapeutics, Inc. - Compugen Ltd. - Oramed Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/2d...1_diabetes
Downtrend Call Working As Halozyme Therapeutics Stock Falls 47.0% (HALO)
Comtex SmarTrend(R) - Tue May 06, 9:36AM CDT
SmarTrend identified a Downtrend for Halozyme Therapeutics (NASDAQ:HALO) on March 13th, 2014 at $13.63. In approximately 2 months, Halozyme Therapeutics has returned 47.03% as of today's recent price of $7.22.
Halozyme to Host first Quarter 2014 Financial Results Conference Call
PR Newswire - Mon May 05, 4:00PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2014 on Monday, May 12, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the first quarter 2014.
46.5% Return Seen to Date on SmarTrend Halozyme Therapeutics Call (HALO)
Comtex SmarTrend(R) - Tue Apr 29, 9:08AM CDT
SmarTrend identified a Downtrend for Halozyme Therapeutics (NASDAQ:HALO) on March 13th, 2014 at $13.63. In approximately 2 months, Halozyme Therapeutics has returned 46.52% as of today's recent price of $7.29.
Global Metastatic Pancreatic Cancer Therapeutics Pipeline Review 2014 - Analysis of 27 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gctlqw/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Pancreatic Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Adherex Technologies Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - FibroGen, Inc. - Novartis AG - Pfizer Inc. - Celgene Corporation - Bayer AG - Halozyme Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - Immunomedics, Inc. - Synta Pharmaceuticals Corp. - NanoCarrier Co., Ltd. - Rexahn Pharmaceuticals, Inc. - Insys Therapeutics, Inc. - OncoMed Pharmaceuticals, Inc. - Merrimack Pharmaceuticals, Inc. - Pharma Mar, S.A. - AB Science - Oncovir, Inc. - ParinGenix, Inc. - Regulon Inc. - Fountain Biopharma Inc. - Oncozyme Pharma Inc. - AbbVie Inc. Drug Profiles - paclitaxel albumin-bound - irinotecan sucrosofate liposomal - masitinib - cisplatin liposomal - cisplatin - refametinib - selumetinib sulfate - trametinib dimethyl sulfoxide - docetaxel - paclitaxel albumin-bound - ganetespib - RX-0201 - irinotecan sucrosofate liposomal - PGX-100 - lurbinectedin - yttrium Y 90 clivatuzumab tetraxetan - Cancer Inhibitor Macrobeads - TL-118 - LY-2090314 - hydroxychloroquine - LY-2495655 - PEGPH-20 - M-402 - pentamidine isethionate - veliparib - galunisertib - ADH-1 - FG-3019 - demcizumab - LCL-161 For more information visit http://www.researchandmarkets.com/research/gctlqw/metastatic
Halozyme Therapeutics Has Returned 43.6% Since SmarTrend Recommendation (HALO)
Comtex SmarTrend(R) - Mon Apr 21, 4:39PM CDT
SmarTrend identified a Downtrend for Halozyme Therapeutics (NASDAQ:HALO) on March 13th, 2014 at $13.63. In approximately 1 month, Halozyme Therapeutics has returned 43.58% as of today's recent price of $7.69.
Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Halozyme Therapeutics, Inc.
Business Wire - Mon Apr 21, 1:02PM CDT
Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of Halozyme Therapeutics, Inc. (NASDAQ: HALO) violated state or federal laws. Halozyme is a biopharmaceutical company that researches, develops and commercializes human enzymes.
1 of These 3 Cratering Biotechs is a Buy
George Budwell, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
At the start of the year, the theme seemed to be that biotech was in for another banner year, propelled by a suite of newly launch drugs that would go on to become blockbusters. These rosy prognostications were made despite broad-based biotech funds...
Robbins Arroyo LLP Is Investigating the Officers and Directors of Halozyme Therapeutics, Inc. on Behalf of Shareholders
PR Newswire - Thu Apr 17, 3:20PM CDT
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Halozyme Therapeutics, Inc. (NASDAQ: HALO) breached their fiduciary duties to shareholders. Halozyme is a biopharmaceutical company that researches, develops, and commercializes human enzymes that facilitate the delivery of injected drugs and fluids.
Coca-Cola and MasterCard are big market movers
AP - Tue Apr 15, 4:01PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
5 of Last Week's Biggest Losers
Rick Munarriz, The Motley Fool - Motley Fool - Sun Apr 13, 6:00AM CDT
There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers. Company April 11 Weekly Loss voxeljet AG $15.10 40% World...
Nasdaq stocks posting largest percentage increases
AP - Fri Apr 11, 12:52PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Halozyme Study Under Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:40PM CDT
Halozyme announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on patient enrollment and dosing of PEGPH20 in an ongoing phase II study.
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 09, 11:46AM CDT
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.
Halozyme Announces Clinical Hold of PEGPH20 Pancreatic Cancer Trial Following Voluntary Halt of Trial by Halozyme
PR Newswire - Wed Apr 09, 7:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the United States Food and Drug Administration (FDA) informed the company yesterday that a clinical hold has been placed on patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer. According to the FDA, this action was being taken in view of the company's recent decision to temporarily halt enrollment and dosing of PEGPH20 in the Phase 2 trial.
Healthcare Companies Report Regulatory Affirmations, MPA Inspections, Enrollment in Trials, Stock Movements - Analyst Notes on Halozyme, Align Technology, Cambrex, Receptos, and Anacor Pharmaceuticals
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Halozyme Therapeutics, Inc. (NASDAQ: HALO), Align Technology Inc. (NASDAQ: ALGN), Cambrex Corporation. (NYSE: CBM), Receptos, Inc. (NASDAQ: RCPT), and Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
3 Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 08, 12:45PM CDT
Just as we examine companies each week that may be rising past their fair values , we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with stocks wallowing at 52-week lows, I think...
Halozyme Falls on Phase II Study Halt - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 11:10AM CDT
Halozyme's shares fell after the company announced its decision to temporarily halt patient enrollment and dosing of PEGPH20 in phase II study.
(0)
(0)